Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB598 · 1 trial · 12 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort 1 | EXPERIMENTAL | Participants will receive AB598 intravenous (IV) infusion once every 3 weeks |
| Dose Escalation Cohort 2 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Dose Escalation Cohort 3 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Dose Escalation Cohort 4 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Pharmacodynamic Cohort 1 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Pharmacodynamic Cohort 2 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Pharmacodynamic Cohort 3 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Dose Expansion Gastric/GEJ Cancer (phase 1b) | EXPERIMENTAL | Participants will receive AB598 IV infusion every 2 weeks in combination with zimberelimab and FOLFOX (oxaliplatin, leucovorin, fluorouracil) |
| Name | Type | Description |
|---|---|---|
| AB598 | DRUG | Administered as specified in the treatment arm |
| Zimberelimab | DRUG | Administered as specified in the treatment arm |
| Fluorouracil | DRUG | Administered as specified in the treatment arm |
| Leucovorin | DRUG | Administered as specified in the treatment arm |
| Oxaliplatin | DRUG | Administered as specified in the treatment arm |
Key Inclusion Criteria: * Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) guidance * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Prior systemic radiation or whole brain radiation therapy must have been completed at ...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AB598 is an investigational small molecule being developed by Arcus Biosciences for the treatment of advanced cancer. It is a CD39-targeted agent and is currently in Phase 1 clinical development. It is not yet approved for any indication and remains under study in a single active trial.
AB598 is being studied for advanced malignancies, including bladder cancer, cervical cancer, esophageal cancer, gastric and gastroesophageal-junction cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, and triple negative breast cancer. It is investigational and has not been approved for any of these uses.
AB598 targets CD39, an enzyme involved in the adenosine pathway within the tumor microenvironment. By acting on CD39, the small molecule is designed to modulate this pathway in cancer. The Phase 1 study evaluates AB598 both as monotherapy and in combination therapy in participants with advanced cancers.
AB598 is being developed by Arcus Biosciences, Inc., a biopharmaceutical company that trades under the ticker RCUS. Arcus is running the clinical program for the asset, which is currently in Phase 1 development for advanced cancer.
AB598 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The ongoing study is a first-in-human style Phase 1 trial evaluating the drug in participants with advanced cancers.
AB598 is being evaluated in the Phase 1 trial NCT05891171, titled Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers. The trial has an enrollment of 40 participants, is active but not recruiting, and is conducted in the United States, Australia, and Taiwan.